There are currently 67 active clinical trials seeking participants for Ulcerative Colitis research studies. The states with the highest number of trials for Ulcerative Colitis participants are Florida, California, Texas and New York.
Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease
Recruiting
Inflammatory Bowel Disease (IBD) are chronic diseases of the gut comprising Crohn's Disease (CD) and Ulcerative Colitis (UC). The symptoms of IBD consist of diarrhea, abdominal discomfort, weight loss, fatigue and rectal bleeding. However, symptoms and treatment vary between patients. Early management of IBD can lead to better response rates and decrease the risk of irreversible bowel damage and future disease complications such as surgeries. Current clinical tools for diagnosis and or assessing... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/06/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: IBD, Crohn Disease, Ulcerative Colitis
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
Recruiting
The purpose of this study is to determine the safety and efficacy of using remestemcel-L, an ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product (MSCs) delivered by targeted endoscopic delivery to treat people for medically refractory ulcerative colitis. This study will enroll adult patients with medically refractory ulcerative colitis who are planning to switch biologic therapy or undergo colectomy as the next stage in their treatment plan.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Ulcerative Colitis
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participa... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/03/2025
Locations: Phoenix Children's Hospital /ID# 250135, Phoenix, Arizona +78 locations
Conditions: Ulcerative Colitis
Immune Regulation in Ulcerative Colitis or Crohn s Disease
Recruiting
This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal tract (stomach and intestines)-specifically, how lymphocytes (a type of white blood cell) function in inflammatory responses. This protocol does not involve any experimental treatments. Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible fo... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
01/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Inflammatory Bowel Disease, Ulcerative Colitis, Chrohn's Disease
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Recruiting
Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improv... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/30/2025
Locations: Future Innovative Treatments, Colorado Springs, Colorado +43 locations
Conditions: Ulcerative Colitis
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/30/2025
Locations: Arizona Digestive Health, Sun City, Arizona +113 locations
Conditions: Ulcerative Colitis
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult participants with moderate to severe UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Gastro SB /ID# 258331, Chula Vista, California +178 locations
Conditions: Ulcerative Colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Digestive Health Specialists, Dothan, Alabama +366 locations
Conditions: Ulcerative Colitis
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2025
Locations: Southern California GI and Liver Centers (SCLC), Coronado, California +82 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Recruiting
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
01/21/2025
Locations: Rady Children's Hospital- San Diego, San Diego, California +55 locations
Conditions: Ulcerative Colitis
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
Recruiting
This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/20/2025
Locations: IHS Health Research, Kissimmee, Florida +16 locations
Conditions: Ulcerative Colitis
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.
Gender:
ALL
Ages:
Between 2 years and 19 years
Trial Updated:
01/20/2025
Locations: UCSF Medical Center at Mission Bay, San Francisco, California +49 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease